In addition to the shares sold in the underwritten public offering, Lexicon granted the underwriters a 30-day option to purchase up to an additional 4,800,000 shares of common stock at the public ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

As of Friday, January 30, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 16.32%, which has investors ...

Investing.com -- Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock fell 14.9% Friday after the company announced the pricing of ...

Lexicon Pharma (LXRX) prices 32M-share offering at $1.30 and $41M+ private placement to fund R&D and working capital—get the key details now.

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label encompasses heart failure patients across the full range of left ventricular ejection fraction ...

Investors might want to bet on Lexicon Pharmaceuticals (LXRX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.